{"id":123594,"date":"2025-04-23T21:51:29","date_gmt":"2025-04-23T21:51:29","guid":{"rendered":"https:\/\/teknomers.com\/en\/is-amgen-inc-amgn-an-inexpensive-nasdaq-investment-recommended-by-hedge-funds\/"},"modified":"2025-04-23T21:51:29","modified_gmt":"2025-04-23T21:51:29","slug":"is-amgen-inc-amgn-an-inexpensive-nasdaq-investment-recommended-by-hedge-funds","status":"publish","type":"post","link":"https:\/\/teknomers.com\/en\/is-amgen-inc-amgn-an-inexpensive-nasdaq-investment-recommended-by-hedge-funds\/","title":{"rendered":"Is Amgen Inc. (AMGN) an Inexpensive NASDAQ Investment Recommended by Hedge Funds?"},"content":{"rendered":"

What recent trends have been identified in the tech sector according to Dan Ives? What impact have escalating tariffs on China had on tech companies? How does Amgen Inc. (NASDAQ:AMGN) compare to other cheap NASDAQ stocks in terms of hedge fund interest? What are the sales trends for Amgen\u2019s key drugs, Repatha and EVENITY? What potential does Amgen’s new obesity medication, MariTide, hold for the market?<\/strong><\/p>\n

In the article, it’s highlighted that Dan Ives of Wedbush Securities has expressed concerns about the tech sector heading into major volatility, particularly with large tech purchases being delayed due to a backdrop of escalating tariffs, significantly impacting firms’ spending behavior as they approach earnings season. Furthermore, Amgen Inc. is discussed in terms of its standing amongst cheap NASDAQ stocks, showcasing a strong presence with a forward P\/E ratio of 13.33 and 72 hedge fund holders. The company has reported impressive sales growth for its therapeutic products, particularly Repatha, which has achieved over $2.2 billion in sales, reflecting a strong demand amidst the current challenges in the healthcare sector. Additionally, prospects for Amgen’s novel obesity medication, MariTide, are promising, as it has shown potential in early trials to carve out market share despite competition from established leaders.<\/p>\n

Is Amgen Inc. (AMGN) a Cheap NASDAQ Stock to Buy According to Hedge Funds?<\/strong><\/p>\n

Amgen Inc. (NASDAQ: AMGN), one of the largest biotechnology companies globally, has made headlines recently for its stock performance and potential investment opportunities. The question gripping investors and analysts alike is whether AMGN represents a cheap stock to buy, especially in light of insights from hedge funds. With its robust product pipeline, market positioning, and the landscape of stock valuations, it’s crucial to analyze whether Amgen is a worthy addition to investment portfolios.<\/p>\n

Amgen\u2019s Market Position<\/h3>\n

Amgen was founded in 1980 and has established itself as a leader in biopharmaceuticals. The company’s portfolio includes pioneering therapies for serious illnesses, focusing on areas like oncology, cardiovascular disease, inflammation, and bone health. With more than 30 years of operational history and significant R&D investments, Amgen has cultivated a strong reputation for innovation.<\/p>\n

Despite the recent changes in the pharmaceutical landscape, namely rising competition and pressure to lower drug prices, Amgen has maintained a steady revenue stream with a diverse portfolio. Key products like Repatha and Otezla continue to drive substantial sales alongside an expanding lineup of biosimilars. Furthermore, the introduction of therapies like teplizumab, a groundbreaking treatment for Type 1 diabetes, illustrates Amgen\u2019s commitment to developing new therapies that can capture market share.<\/p>\n

Valuation Metrics<\/h3>\n

Investors often gauge whether a stock is "cheap" based on various financial metrics, including Price-to-Earnings (P\/E) ratios, Price-to-Sales (P\/S) ratios, and projected earnings growth. As of the latest analysis, Amgen\u2019s P\/E ratio stands at a compelling number compared to its industry peers. With the biotechnology sector generally having higher P\/E ratios due to the substantial risk associated with drug development, Amgen’s valuations appear attractive.<\/p>\n

Moreover, the company has consistently delivered dividends, aligning with the strategies of income-focused investors. The dividend yield for AMGN is approximately 3%, which is higher than the average yield in the biotechnology sector. This combination of steady dividends and a reasonable valuation makes AMGN an appealing option for investors seeking both growth and income.<\/p>\n

Hedge Fund Activity<\/h3>\n

Hedge funds are often seen as market barometers, with their buying and selling activities providing signals to other investors. Amgen has attracted significant interest from hedge funds lately, indicating that professional managers see value in its current price levels. According to data, a notable number of hedge funds have increased their stakes in the company, with some citing Amgen’s strong fundamentals and promising future prospects as reasons for their investments.<\/p>\n

In the latest quarter, some of the most prominent hedge funds have made sizable additions to their positions in AMGN. This trend is particularly telling \u2014 when seasoned investors show confidence in a stock, it can often lead to more robust price performance. It’s important, however, to analyze the motivations behind these moves. Many hedge funds rely on extensive research and analytics, often leading to insights that individual investors may overlook.<\/p>\n

Potential Risks<\/h3>\n

While Amgen\u2019s prospects look promising, risks remain that investors must consider. Industry-specific threats, such as regulatory challenges, increased competition from generic drugs, and an uncertain healthcare policy environment, can impact stock performance. Recent trends suggest that pricing pressure from governments and insurers could affect future revenue growth, compelling the company to adapt its pricing strategies to maintain profits.<\/p>\n

Moreover, the company must continually invest in R&D to stay competitive. The biotech industry is notorious for its high failure rates in drug development, which mandates companies like Amgen to be agile and adaptive. As it expands its pipeline, any delays or failures in clinical trials could lead to a downturn in market sentiment towards the stock.<\/p>\n

Conclusion<\/h3>\n

In conclusion, Amgen Inc. (AMGN) appears to present a compelling case for being a cheap stock on the NASDAQ, particularly according to the movements of hedge funds. With its attractive valuation metrics, consistent dividend payouts, and positive hedge fund sentiment, many investors may view AMGN as an ideal choice for long-term growth and income.<\/p>\n

However, it is essential to understand the inherent risks associated with the biotech sector and to consider the company’s strategic approaches to overcoming these challenges. Consequently, while Amgen may indeed reflect a "buy" signal for many investors, thorough research and understanding of one\u2019s risk appetite are crucial for making informed investment decisions. As always, consulting with financial advisors or conducting personal due diligence can provide additional layers of insight before investing in any stock.<\/p>\n

To determine if Amgen Inc. (AMGN) is considered a cheap NASDAQ stock by hedge funds, we should analyze a few key factors:<\/p>\n

    \n
  1. \n

    Valuation Metrics<\/strong>: Examine Amgen’s price-to-earnings (P\/E) ratio, price-to-book (P\/B) ratio, and price-to-sales (P\/S) ratio compared to industry averages and historical values. If these metrics are lower than peers, it might indicate that the stock is undervalued.<\/p>\n<\/li>\n

  2. \n

    Hedge Fund Activity<\/strong>: Look at hedge fund ownership data for AMGN. Significant increases in holdings or a high percentage of hedge funds owning the stock can indicate bullish sentiment among institutional investors.<\/p>\n<\/li>\n

  3. \n

    Market Conditions<\/strong>: Consider the broader market environment, including how biotech and pharmaceutical stocks are performing relative to other sectors. Economic factors and regulatory changes can also influence stock valuations.<\/p>\n<\/li>\n

  4. \n

    Company Fundamentals<\/strong>: Review Amgen\u2019s earnings growth, revenue trends, and pipeline developments. Strong fundamentals can justify a higher valuation, while weak fundamentals might suggest a discounted price.<\/p>\n<\/li>\n

  5. Analyst Ratings<\/strong>: Analyze recent analyst recommendations and target prices from reputable sources. If analysts view the stock as undervalued, it could reflect a consensus that it is a good buying opportunity.<\/li>\n<\/ol>\n

    By synthesizing this information, investors can make an informed decision about whether AMGN is a cheap stock to buy according to hedge funds.<\/p>\n

    Tm-En-7<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    What recent trends have been identified in the tech sector according to Dan Ives? What impact have escalating tariffs on China had on tech companies? How does Amgen Inc. (NASDAQ:AMGN) compare to other cheap NASDAQ stocks in terms of hedge fund interest? What are the sales trends for Amgen\u2019s key drugs, Repatha and EVENITY? What […]<\/p>\n","protected":false},"author":1,"featured_media":108984,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23832],"tags":[],"class_list":["post-123594","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/123594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/comments?post=123594"}],"version-history":[{"count":0,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/123594\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media\/108984"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media?parent=123594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/categories?post=123594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/tags?post=123594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}